JERUSALEM, Israel--(BUSINESS WIRE)--Jan. 27, 2006--Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that it priced its offering, through several special purpose finance subsidiaries, of $750 million of 1.75% convertible senior debentures maturing in 2026, which may be redeemed by Teva’s finance subsidiary in five years and repurchased by Teva’s finance subsidiary at investors’ option in five, ten or fifteen years and $500 million of 0.25% convertible senior debentures maturing in 2026, which may be redeemed by Teva’s finance subsidiary in two years and repurchased by Teva’s finance subsidiary at investors’ option in two, five, ten or fifteen years.
